Clinical Trials
17 trialsNCT07551349 2026-04-24
DUAL-NK RCC
Beijing Biotech
Phase 1/2 Recruiting
NCT07523529 2026-04-13
SELECT-2CAR
Beijing Biotech
Phase 1/2 Recruiting
NCT07492628 2026-03-25
DUET-UC-NK
Beijing Biotech
Phase 1 Recruiting
NCT04696731 2025-09-25
TRAVERSE
Allogene Therapeutics
Phase 1 Active not recruiting
NCT06480565 2025-08-15
A Phase 1/2 Trial of ADI-270 in ccRCC
Adicet Therapeutics
Phase 1/2 Active not recruiting
NCT04319757 2024-12-05
ACE1702 in Subjects With Advanced or Metastatic HER2-expressing Solid Tumors
Acepodia Biotech, Inc.
Phase 1 Completed
NCT06505551 2024-07-17
Phase 1/2 Study of Autologous SCG142 TCR T Cells in Patients With HPV16/52-positive Carcinoma
SCG Cell Therapy Pte. Ltd.
Phase 1/2 Not yet recruiting
NCT04633148 2024-04-23
Dose-escalating Trial With UniCAR02-T Cells and PSMA Target Module (TMpPSMA) in Patients With Progressive Disease After Standard Systemic Therapy in Cancers With Positive PSMA Marker
AvenCell Therapeutics, Inc.
Phase 1 Terminated
NCT05787535 2024-02-02
HRYZ-T101 TCR-T Cell for HPV-18 Positive Advanced Solid Tumor
HRYZ Biotech Co.
Phase 1 Unknown
NCT05952947 2024-02-02
HRYZ-T101 Injection for HPV18 Positive Solid Tumor
HRYZ Biotech Co.
Phase 1 Recruiting
NCT04551885 2023-09-21
FT516 in Combination With Monoclonal Antibodies in Advanced Solid Tumors
Fate Therapeutics
Phase 1 Terminated
NCT05069935 2023-09-21
FT538 in Combination With Monoclonal Antibodies in Advanced Solid Tumors
Fate Therapeutics
Phase 1 Terminated
NCT04227275 2023-08-21
A Study of CART-PSMA-TGFβRDN in Patients With Metastatic Castration Resistant Prostate Cancer
Tceleron Therapeutics, Inc.
Phase 1 Terminated
NCT03841110 2023-05-01
FT500 as Monotherapy and in Combination With Immune Checkpoint Inhibitors in Subjects With Advanced Solid Tumors
Fate Therapeutics
Phase 1 Completed
NCT03692663 2022-08-01
Study of Anti-PSMA CAR NK Cell (TABP EIC) in Metastatic Castration-Resistant Prostate Cancer
Allife Medical Science and Technology Co., Ltd.
Phase EARLY_PHASE1 Unknown
NCT04596033 2022-07-15
TiTAN-1: Safety, Proliferation and Persistence of GEN-011 Autologous Cell Therapy
Genocea Biosciences, Inc.
Phase 1 Terminated
NCT00625430 2011-07-11
FP253-GDEPT
Biotech Equity Partners Pty Ltd
Phase 1 Unknown